Premium
Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody: An indicator of poor prognosis
Author(s) -
Loke Richard H. T.,
MurrayLyon Iain M.,
Coleman John C.,
Evans Brian A.,
Zuckerman Arie J.
Publication year - 1990
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.1890310207
Subject(s) - seroconversion , medicine , virology , antibody , recombinant dna , immunology , hepatitis b vaccine , hepatitis b virus , hepatitis b , viral disease , human immunodeficiency virus (hiv) , hepadnaviridae , virus , hbsag , biology , biochemistry , gene
Three doses of a recombinant DNA HBV vaccine (MSD) were given to healthy male homosexuals. Seventy‐eight out of 104 (77.6%) participants had detectable antibody (anti‐HBs) two months after the third dose. Seroconversion occurred in only 9 out of 27 subjects (33.3%) who were anti‐HIV positive compared with 69 out of 77 (89.6%) who were negative (χ 2 = 30.8; P < .001). Fifteen of the 18 anti‐HIV positive who did not mount an antibody response to the hepatitis B vaccine (anti‐HBs) later progressed to persistent generalised lymphadenopathy syndrome (5), AIDS‐related complex (5), and AIDS (5). Only one of the nine anti‐HIV positive anti‐HBs responders developed PGL (χ 2 = 10.14; P < .005). Our results show that anti‐HIV positive homosexuals are poor responders to the recombinant hepatitis B vaccine and anti‐HIV positive non‐responders are more likely to develop clinically apparent HIV infection.